Alzheimers research shows period pain-killer completely reverses memory loss
A study in mice found that the anti-inflammatory drug mefenamic acid reversed memory loss and brain inflammation in an Alzheimers disease model by targeting the NLRP3 inflammasome. Researchers caution that effects in humans are unknown and plan early-phase II trials, highlighting the potential of repurposing an existing drug to accelerate dementia drug development.
New mouse model suggests how Alzheimers causes dementia
Beta-amyloid plaque accumulation can damage the brain but is not sufficient to trigger the conversion of tau or the full neurodegenerative process. A second insultthe conversion of taudriven by signaling events, may be required, implying that therapies targeting both amyloid and tau conversion, and doing so before tau changes occur, could be more effective.